GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eton Pharmaceuticals Inc (NAS:ETON) » Definitions » Earnings per Share (Diluted)

Eton Pharmaceuticals (Eton Pharmaceuticals) Earnings per Share (Diluted) : $0.04 (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eton Pharmaceuticals Earnings per Share (Diluted)?

Eton Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.03. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.04.

Eton Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.04.

Eton Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was $-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $0.04.

During the past 3 years, the average EPS without NRIGrowth Rate was 68.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 57.90% per year.

During the past 7 years, Eton Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 73.40% per year. The lowest was 29.60% per year. And the median was 68.90% per year.


Eton Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Eton Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eton Pharmaceuticals Earnings per Share (Diluted) Chart

Eton Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial -1.03 -1.33 -0.08 -0.36 -0.04

Eton Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 0.18 -0.02 -0.09 -0.03

Competitive Comparison of Eton Pharmaceuticals's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eton Pharmaceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Eton Pharmaceuticals's PE Ratio falls into.



Eton Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Eton Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.936-0)/25.645
=-0.04

Eton Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.811-0)/25.763
=-0.03

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Eton Pharmaceuticals  (NAS:ETON) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Eton Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Eton Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Eton Pharmaceuticals (Eton Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development.
Executives
David Krempa officer: Chief Business Officer 29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Sean Brynjelsen director, officer: President & CEO C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
James R. Gruber officer: Chief Financial Officer 618 AMES STREET, LIBERTYVILLE IL 60048
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
William Wilson Troutman officer: CFO, Treasurer & Secretary 21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Imprimis Pharmaceuticals, Inc. 10 percent owner 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215
Jennifer Mckie Adams director 5410 TENNESSEE AVE, NASHVILLE TN 37209
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Mark L Baum director C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121

Eton Pharmaceuticals (Eton Pharmaceuticals) Headlines